Health
Kyverna Therapeutics’ CAR-T Therapy Delivers Strong Phase 2 Results in Rare Stiff Person Syndrome
Kyverna’s (NASDAQ:KYTX) miv-cel posts robust efficacy and manageable safety in the KYSA-8 trial, paving the way for a planned 2026 BLA filing.
United States Health
Health
argenx discontinues Phase 3 TED studies on efgartigimod SC due to futility
Argenx (ARGX) announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod SC in Thyroid Eye Disease (TED) after an interim analysis by an Independent Data Monitoring Committee (IDMC) indicated futility.
Health
Philips to buy SpectraWAVE to bolster AI-driven coronary imaging portfolio
Royal Philips announced an agreement to acquire SpectraWAVE, a Boston-area medical device company, integrating its advanced HyperVue imaging and AI-enabled FFR technology into Philips’ image-guided therapy suite.
Health
Natera and MEDSIR collaborate on MiRaDoR Phase II study in HR+/HER2- breast cancer
Natera (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study.
Health
Acadia Pharmaceuticals receives FDA approval for DAYBUE® STIX for Rett syndrome treatment
Acadia Pharmaceuticals (NASDAQ:ACAD) announced today that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a new dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in both adult and pediatric patients aged two years and older.
Health
Relay Therapeutics reports positive subset efficacy data for zovegalisib in combination with fulvestrant
Relay Therapeutics (NASDAQ:RLAY) presented promising subset efficacy data from its ReDiscover program at the 2025 San Antonio Breast Cancer Symposium (SABCS), showcasing the combination of zovegalisib (RLY-2608) and fulvestrant in a cohort of 52 patients with estrogen receptor-positive breast cancer.
Health
BeyondSpring unveils positive Asian subset results from Phase 3 DUBLIN-3 trial
BeyondSpring (NASDAQ:BYSI) presented encouraging results from the Asian subset of its global Phase 3 DUBLIN-3 trial at ESMO Asia 2025, evaluating the combination of plinabulin and docetaxel versus docetaxel alone in second-line and third-line EGFR wild-type non-small cell lung cancer (NSCLC).
Health
OKYO Pharma reports exploratory Phase 2 data for urcosimod in neuropathic corneal pain
OKYO Pharma (NASDAQ:OKYO) announced on December 11, 2025, new analyses from its Phase 2, placebo-controlled, randomized, double-masked trial of 0.05% urcosimod for the treatment of neuropathic corneal pain (NCP).
The trial, involving 18 patients, provided exploratory data on corneal nerve imaging using in vivo confocal microscopy.